TapewireFind a company

person · Reporting owner

Stone Paul A.

Disclosed activity across 1 company

Tapewire entity
110079
SEC CIK
0001777511

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
IDEAYA Biosciences, Inc.IDYA · Entity 4069Chief Financial OfficerAugust 29, 2023August 31, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

IDEAYA Biosciences, Inc.

Report date August 29, 2023 · Filed August 31, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect9,303 Reported balance After 2023-08-29 transaction · row 1
1 source row

Row 1 · 2023-08-29 · Sale · Disposed 5,000 · Balance 9,303

F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 27, 2023.

F2: This transaction was executed in multiple trades in prices ranging from $28.83 to $29.02, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 27, 2023.

F2: This transaction was executed in multiple trades in prices ranging from $28.83 to $29.02, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 29, 2023 Filed Aug 31, 2023 17:49 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 SaleCommon Stock 5,000 $28.87 $144,351.50
Disclosure

SEC source: 0001610717-23-000251 · form4.xml · nonDerivative · entry 1

Stone Paul A. · CIK 0001777511 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,303

F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 27, 2023.

F2 · price: This transaction was executed in multiple trades in prices ranging from $28.83 to $29.02, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
August 21, 2023 Filed Aug 23, 2023 18:31 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 SaleCommon Stock 978 $26.40 $25,819.49
Disclosure

SEC source: 0001610717-23-000234 · form4.xml · nonDerivative · entry 1

Stone Paul A. · CIK 0001777511 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,303

F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 27, 2023.

F2 · price: This transaction was executed in multiple trades in prices ranging from $26.38 to $26.4175, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
August 18, 2023 Filed Aug 18, 2023 18:33 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 SaleCommon Stock 3,822 $26.38 $100,820.16
Disclosure

SEC source: 0001610717-23-000233 · form4.xml · nonDerivative · entry 3

Stone Paul A. · CIK 0001777511 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,281

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 27, 2023.

F2 · price: This transaction was executed in multiple trades in prices ranging from $26.37 to $26.415, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
August 16, 2023 Filed Aug 18, 2023 18:33 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 SaleCommon Stock 100 $26.40 $2,640.00
Disclosure

SEC source: 0001610717-23-000233 · form4.xml · nonDerivative · entry 2

Stone Paul A. · CIK 0001777511 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,103

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 27, 2023.

Read SEC document
August 16, 2023 Filed Aug 18, 2023 18:33 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 SaleCommon Stock 100 $26.45 $2,645.00
Disclosure

SEC source: 0001610717-23-000233 · form4.xml · nonDerivative · entry 1

Stone Paul A. · CIK 0001777511 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,203

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 27, 2023.

Read SEC document
August 09, 2023 Filed Aug 11, 2023 19:21 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 SaleCommon Stock 2,500 $25.05 $62,613.25
Disclosure

SEC source: 0001610717-23-000225 · form4.xml · nonDerivative · entry 1

Stone Paul A. · CIK 0001777511 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,303

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 27, 2023.

F2 · price: This transaction was executed in multiple trades in prices ranging from $25.00 to $25.105, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
April 13, 2023 Filed Apr 14, 2023 13:20 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 Exercise / conversionStock Option (right to buy) · Derivative 8,000 $0.00 Strike: $4.62 $0.00
Disclosure

SEC source: 0001610717-23-000009 · form4.xml · derivative · entry 2

Stone Paul A. · CIK 0001777511 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 129,832

Underlying: Common Stock · 8,000 shares

Expires 2028-06-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable.

Read SEC document
April 13, 2023 Filed Apr 14, 2023 13:20 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 Exercise / conversionCommon Stock 8,000 $4.62 $36,960.00
Disclosure

SEC source: 0001610717-23-000009 · form4.xml · nonDerivative · entry 1

Stone Paul A. · CIK 0001777511 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,803

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · balance_after: The amount reported herein has been adjusted to correct an error in Column 5 of Table I in a Form 4 previously filed on April 14, 2022.

Read SEC document
February 24, 2023 Filed Feb 28, 2023 17:01 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 GrantStock Option (right to buy) · Derivative 140,000 $0.00 Strike: $17.04 $0.00
Disclosure

SEC source: 0001567619-23-003947 · doc1.xml · derivative · entry 1

Stone Paul A. · CIK 0001777511 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,000

Underlying: Common Stock · 140,000 shares

Expires 2033-02-23

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Read SEC document
March 01, 2022 Filed Mar 2, 2022 19:46 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 GrantStock Option (right to buy) · Derivative 92,500 $0.00 Strike: $12.86 $0.00
Disclosure

SEC source: 0001567619-22-006126 · doc1.xml · derivative · entry 1

Stone Paul A. · CIK 0001777511 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,500

Underlying: Common Stock · 92,500 shares

Expires 2032-02-29

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Read SEC document
September 07, 2021 Filed Sep 9, 2021 17:41 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 SaleCommon Stock 2,500 $27.42 $68,542.50
Disclosure

SEC source: 0001567619-21-016924 · doc1.xml · nonDerivative · entry 1

Stone Paul A. · CIK 0001777511 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,944

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades in prices ranging from $27.37 to $27.57, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
May 28, 2021 Filed Apr 14, 2022 16:10 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 GrantCommon Stock 859 $11.36 $9,762.11
Disclosure

SEC source: 0001567619-22-008545 · doc1.xml · nonDerivative · entry 1

Stone Paul A. · CIK 0001777511 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,803

F1 · shares: Acquired pursuant to Issuer's Employee Stock Purchase Plan.

Read SEC document
February 24, 2021 Filed Feb 26, 2021 19:07 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 GrantStock Option (right to buy) · Derivative 80,000 $0.00 Strike: $19.52 $0.00
Disclosure

SEC source: 0001567619-21-005111 · doc1.xml · derivative · entry 1

Stone Paul A. · CIK 0001777511 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2031-02-23

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Read SEC document
December 11, 2020 Filed Dec 15, 2020 16:15 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 OtherCommon Stock 444 $0.00 $0.00
Disclosure

SEC source: 0001567619-20-021089 · doc1.xml · nonDerivative · entry 1

Stone Paul A. · CIK 0001777511 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,444

F1 · kind: Pro rata in-kind distribution from 5AM Partners IV, LLC for no consideration.

Read SEC document
June 17, 2020 Filed Jun 19, 2020 19:46 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 Exercise / conversionStock Option (right to buy) · Derivative 3,100 $0.00 Strike: $4.62 $0.00
Disclosure

SEC source: 0001567619-20-012462 · doc1.xml · derivative · entry 4

Stone Paul A. · CIK 0001777511 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 137,832

Underlying: Common Stock · 3,100 shares

Expires 2028-06-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from May 2, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Read SEC document
June 17, 2020 Filed Jun 19, 2020 19:46 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 SaleCommon Stock 600 $19.95 $11,968.02
Disclosure

SEC source: 0001567619-20-012462 · doc1.xml · nonDerivative · entry 3

Stone Paul A. · CIK 0001777511 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F3 · price: This transaction was executed in multiple trades in prices ranging from $19.83 to $19.97, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
June 17, 2020 Filed Jun 19, 2020 19:46 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 SaleCommon Stock 2,500 $17.50 $43,748.75
Disclosure

SEC source: 0001567619-20-012462 · doc1.xml · nonDerivative · entry 2

Stone Paul A. · CIK 0001777511 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,600

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades in prices ranging from $17.48 to $17.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
June 17, 2020 Filed Jun 19, 2020 19:46 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 Exercise / conversionCommon Stock 3,100 $4.62 $14,322.00
Disclosure

SEC source: 0001567619-20-012462 · doc1.xml · nonDerivative · entry 1

Stone Paul A. · CIK 0001777511 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,100

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 30, 2020 Filed Apr 1, 2020 16:06 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 Exercise / conversionStock Option (right to buy) · Derivative 5,000 $0.00 Strike: $4.62 $0.00
Disclosure

SEC source: 0001567619-20-007287 · doc1.xml · derivative · entry 4

Stone Paul A. · CIK 0001777511 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,932

Underlying: Common Stock · 5,000 shares

Expires 2028-06-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from May 2, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Read SEC document
March 30, 2020 Filed Apr 1, 2020 16:06 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 Exercise / conversionCommon Stock 5,000 $4.62 $23,100.00
Disclosure

SEC source: 0001567619-20-007287 · doc1.xml · nonDerivative · entry 1

Stone Paul A. · CIK 0001777511 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 21, 2020 Filed Feb 25, 2020 16:05 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 GrantStock Option (right to buy) · Derivative 80,000 $0.00 Strike: $6.92 $0.00
Disclosure

SEC source: 0001567619-20-004806 · doc1.xml · derivative · entry 1

Stone Paul A. · CIK 0001777511 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2030-02-20

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Read SEC document
July 26, 2019 Filed Jul 29, 2019 16:27 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 Exercise / conversionStock Option (right to buy) · Derivative 10,000 $0.00 Strike: $4.62 $0.00
Disclosure

SEC source: 0001567619-19-015342 · doc1.xml · derivative · entry 4

Stone Paul A. · CIK 0001777511 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,932

Underlying: Common Stock · 10,000 shares

Expires 2028-06-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from May 2, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Read SEC document
July 26, 2019 Filed Jul 29, 2019 16:27 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 Exercise / conversionCommon Stock 10,000 $4.62 $46,200.00
Disclosure

SEC source: 0001567619-19-015342 · doc1.xml · nonDerivative · entry 1

Stone Paul A. · CIK 0001777511 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 28, 2019 Filed May 28, 2019 21:08 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 ConversionSeries B Preferred Stock · Derivative 24,101 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-19-012281 · doc1.xml · derivative · entry 10

Stone Paul A. · CIK 0001777511 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 24,101 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F4 · price: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F4 · derivative.exercise_date: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F4 · derivative.expiration_date: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · derivative.underlying_shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F4 · derivative.underlying_shares: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F5 · ownership.nature: The shares are held by 5AM Co-Investors IV, L.P. Mr. Stone disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Read SEC document
May 28, 2019 Filed May 28, 2019 21:08 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 ConversionSeries A Preferred Stock · Derivative 71,745 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-19-012281 · doc1.xml · derivative · entry 9

Stone Paul A. · CIK 0001777511 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 71,745 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F2 · price: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F2 · derivative.exercise_date: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F2 · derivative.expiration_date: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · derivative.underlying_shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F2 · derivative.underlying_shares: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F5 · ownership.nature: The shares are held by 5AM Co-Investors IV, L.P. Mr. Stone disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Read SEC document
May 28, 2019 Filed May 28, 2019 21:08 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 ConversionSeries B Preferred Stock · Derivative 578,447 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-19-012281 · doc1.xml · derivative · entry 8

Stone Paul A. · CIK 0001777511 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 578,447 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F4 · price: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F4 · derivative.exercise_date: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F4 · derivative.expiration_date: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · derivative.underlying_shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F4 · derivative.underlying_shares: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F3 · ownership.nature: The shares are held by 5AM Ventures IV, L.P. Mr. Stone disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Read SEC document
May 28, 2019 Filed May 28, 2019 21:08 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 ConversionSeries A Preferred Stock · Derivative 1,721,898 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-19-012281 · doc1.xml · derivative · entry 7

Stone Paul A. · CIK 0001777511 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,721,898 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F2 · price: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F2 · derivative.exercise_date: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F2 · derivative.expiration_date: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · derivative.underlying_shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F2 · derivative.underlying_shares: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F3 · ownership.nature: The shares are held by 5AM Ventures IV, L.P. Mr. Stone disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Read SEC document
May 28, 2019 Filed May 28, 2019 21:08 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 PurchaseCommon Stock 10,000 $10.00 $100,000.00
Disclosure

SEC source: 0001567619-19-012281 · doc1.xml · nonDerivative · entry 6

Stone Paul A. · CIK 0001777511 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 118,521

F5 · ownership.nature: The shares are held by 5AM Co-Investors IV, L.P. Mr. Stone disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Read SEC document
May 28, 2019 Filed May 28, 2019 21:08 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 PurchaseCommon Stock 240,000 $10.00 $2,400,000.00
Disclosure

SEC source: 0001567619-19-012281 · doc1.xml · nonDerivative · entry 5

Stone Paul A. · CIK 0001777511 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,844,545

F3 · ownership.nature: The shares are held by 5AM Ventures IV, L.P. Mr. Stone disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Read SEC document
May 28, 2019 Filed May 28, 2019 21:08 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 ConversionCommon Stock 24,101 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-19-012281 · doc1.xml · nonDerivative · entry 4

Stone Paul A. · CIK 0001777511 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 108,521

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F4 · shares: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F4 · price: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · balance_after: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F5 · ownership.nature: The shares are held by 5AM Co-Investors IV, L.P. Mr. Stone disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Read SEC document
May 28, 2019 Filed May 28, 2019 21:08 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 ConversionCommon Stock 71,745 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-19-012281 · doc1.xml · nonDerivative · entry 3

Stone Paul A. · CIK 0001777511 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 84,420

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F2 · shares: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F2 · price: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · balance_after: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F5 · ownership.nature: The shares are held by 5AM Co-Investors IV, L.P. Mr. Stone disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Read SEC document
May 28, 2019 Filed May 28, 2019 21:08 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 ConversionCommon Stock 578,447 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-19-012281 · doc1.xml · nonDerivative · entry 2

Stone Paul A. · CIK 0001777511 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,604,545

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F4 · shares: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F4 · price: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · balance_after: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F3 · ownership.nature: The shares are held by 5AM Ventures IV, L.P. Mr. Stone disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Read SEC document
May 28, 2019 Filed May 28, 2019 21:08 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 ConversionCommon Stock 1,721,898 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-19-012281 · doc1.xml · nonDerivative · entry 1

Stone Paul A. · CIK 0001777511 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,026,098

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F2 · shares: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F2 · price: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · balance_after: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F3 · ownership.nature: The shares are held by 5AM Ventures IV, L.P. Mr. Stone disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.